In support of this conclusion, targeting these pathways together using SB505124 and ruxolitinib suppressed endothelial JAK1 activation in 3D co-cultures of human pancreatic cancer cells (PCCs) and human endothelial cells (ECs), and prevented ECs from exerting proliferative angiocrine effects on PCCs. This evidence concerns the gene JAK1 and familial pancreatic carcinoma.